SEC Form 5 · accession 0001264931-15-000091
Immune Therapeutics, Inc. · IMUN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Christopher Pearce
Officer — CHIEF OPERATING OFFICER · Director
Period of report
Dec 31, 2014
Accepted (ET)
Feb 17, 2015 · 12:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001559356
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1 | Apr 16, 2014 | A | 0 | $0.00 | D | 1,535,000 | D | |
| COMMON STOCK | Nov 25, 2014 | A | 25,000 | $0.00 | D | 2,043,000 | D | |
| COMMON STOCKF3 | Dec 23, 2014 | J | 33,125 | $0.00 | A | 2,076,125 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The total number of shares has been adjusted to delete shares inadvertently included in previous reports.
- F2Inadvertently omitted filing Form 4 for November 25, 2014 transaction. The reporting person did not sell these shares but rather transferred these shares in connection with the reporting person obtaining certain discovery records on behalf of the issuer. All of the reporting person's shares of the issuer's common stock are restricted.
- F3Inadvertently omitted filing Form 4 for December 23, 2014 transaction. The reporting person acquired these shares from the Nicholas P. Plotnikoff Family Trust pursuant to a Second Amended Plan of Liquidation approved by the U.S. Bankruptcy Court for the District of Delaware due to the reporting person's status as an unsecured creditor.